This Delivery App’s Long Game Is To Invest Now and Get Faster Later

Hidden Insight (Sponsored)

The Timing Tool Top Traders Don’t Talk About

This powerful method can identify momentum shifts fast.

It’s been refined by a trader with three decades of success.

While others scramble for signals, this tool helps traders see patterns forming early.

It works in all types of market conditions and cuts out the guesswork.

And now you can learn this rarely discussed strategy directly.

Click here to access it.

Never Miss a Stock Alert Again!

We now send our daily picks via SMS too — so you’ll get the same high-conviction ideas, even if you miss the email.

👉 Click here to get stock picks by text and stay in the loop, always.

Warner Bros. Discovery | WBD

Price: $22.76

Media sharks are circling. Reports say Comcast, Netflix, and Paramount Skydance are lining up bids, with a Nov. 20 soft deadline and WBD already teeing up a split between studios/streaming and legacy cable. 

That means the crown jewels are film, TV, and Max, and old-school linear is the baggage.

An auction, formal or informal, can reprice assets fast, but deals here are complicated by debt, antitrust, and who wants which pieces. 

Still, optionality is real, and YTD the stock has acted like it.

For holders, near-term catalysts are bid headlines and any clarity on what gets sold and when, followed by the math: proceeds, debt reduction, and earnings mix post-transaction.

Why this matters for you: Sum-of-the-parts stories can unlock value if buyers pay up for the good stuff.

Just remember: M&A headlines are fun; closing is hard. Size your excitement accordingly.

Bristol Myers Squibb | BMY

Price: $46.81

Tough update for the company. BMY and J&J stopped the Librexia ACS study after a review said it likely wouldn’t hit its main goal.

Safety looked consistent, and two other Phase 3 trials, AF and STROKE, are still running toward 2026 readouts.

 In big pharma land, pipelines are portfolios: some shots miss, some hit, and your dividend and buyback program bridge the waiting.

BMY’s yield north of 5% softens the blow, but sentiment needs a win or two from oncology/cardiovascular to turn. 

Near-term watch list is the capital allocation discipline, any BD that strengthens late-decade growth, and steady progress in immunology and cell therapy.

Why this matters for you: If you own it for income, the pipeline’s ups and downs come with the territory.

Your edge is patience and diversification, don’t let one trial headline dictate your whole healthcare exposure.

Don’t Wait (Sponsored)

9 AI Opportunities Ready to Accelerate

Beyond the noise, a quiet AI boom is taking shape—one with the potential to spark major breakthroughs in value.

Early indicators suggest nine opportunities are aligning ahead of wider market recognition.

These prospects show strong revenue trajectories, advanced integration across key systems, and domestic readiness for growth.

Everything is detailed in a FREE report outlining all nine opportunities and the factors behind their potential rise.

Download the FREE Report Now.

Netflix | NFLX

Price: $110.29

The streamer is digesting a bumpy quarter. There was a softer guide, a chunky Brazil tax charge that dinged margins, and the stock pulled back from the highs.

Street takes are split, some boosted targets, others tapped the brakes, while rumor mills spin about WBD assets changing hands industry-wide.

The core thesis hasn’t changed much as ads are scaling, password sharing is less of a leak, and content ROI still decides everything. 

The risk is execution slippage at premium multiples, but the opportunity is that NFLX keeps out-producing rivals on global hours watched and ad-tier economics.

Why this matters for you: This is a show-me phase. If subs, engagement, and ad ARPU keep trending up, the post-earnings wobble can fade.

If not, the stock’s rich history of optimism will meet gravity. Track data, not drama.

Workday | WDAY

Price: $224.95

Cloud HR and finance is a grind, not a sprint, and Workday is trying to re-accelerate after a choppy stretch.

The prints were solid, beats on revenue and EPS, with a steady double-digit growth outlook and a path to higher operating margins over time. 

The push-pull is that enterprises remain cautious on new seats, but AI-assisted workflows and wider product breadth (planning, spend, analytics) deepen the moat with existing customers. 

The stock has been rough this year, which leaves more room if the next few quarters show net-new wins and stable renewals.

Why this matters for you: It’s a quality, sticky platform that can compound when IT budgets thaw.

If you want cloud exposure that isn’t just another GPU proxy, this is a calmer way to play digital back-office upgrades.

DoorDash | DASH

Price: $210.65

DoorDash spooked the crowd with a capex-heavy plan, with robots, smarter fulfillment, and an international buildout, but the logic is long-game.

The marketplace is already broad (restaurants, groceries, retail), and faster, cheaper delivery is the retention hack that keeps both users and merchants sticky. 

Third-party takes will always be debated, but better routing and automation can compress unit costs while keeping the app’s convenience edge.

Needham still likes the roadmap, calling out room for 30%-plus EBITDA growth as the investment wave crests. 

Yes, it’s a volatile, competitive arena with regulatory swing risk, and the stock can overshoot in both directions.

But if execution stays tight, scale and software should do their thing.

Why this matters for you: Think of it like paving more lanes on a busy highway.

It slows traffic today, but when it opens, everything moves faster, and that can show up as steadier margins and stickier demand.

Stat of the Day: 26.7% Decline

The Fed’s balance sheet has shrunk by $2.4T from its April 2022 peak, down 26.7% to the lowest since April 2020.

Less liquidity is the slow, dull backdrop to everything: multiples get less air, cash matters more, and companies that self-fund win more often than not.

Final Take
Spend where it builds a moat (DASH), sell what the market overvalues and keep options open (WBD), don’t let one trial define a whole pipeline (BMY), focus on engagement over headlines (NFLX), and prefer sticky software with operating leverage (WDAY).

Same playbook as always: start small, let proof points earn your conviction, and keep dry powder for when the crowd gets loud.